Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Change in Cash (2021 - 2025)

Historic Change in Cash for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to -$22.6 million.

  • Molecular Partners Ag's Change in Cash fell 130865.15% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year increase of 7987.81%. This contributed to the annual value of -$3.9 million for FY2024, which is 8321.71% up from last year.
  • Latest data reveals that Molecular Partners Ag reported Change in Cash of -$22.6 million as of Q3 2025, which was down 130865.15% from $21.8 million recorded in Q2 2025.
  • Over the past 5 years, Molecular Partners Ag's Change in Cash peaked at $44.7 million during Q2 2022, and registered a low of -$67.1 million during Q4 2021.
  • In the last 5 years, Molecular Partners Ag's Change in Cash had a median value of -$15153.6 in 2023 and averaged -$4.1 million.
  • The largest annual percentage gain for Molecular Partners Ag's Change in Cash in the last 5 years was 153970.99% (2025), contrasted with its biggest fall of 130865.15% (2025).
  • Quarter analysis of 5 years shows Molecular Partners Ag's Change in Cash stood at -$67.1 million in 2021, then surged by 124.97% to $16.7 million in 2022, then crashed by 238.78% to -$23.2 million in 2023, then skyrocketed by 83.14% to -$3.9 million in 2024, then tumbled by 476.77% to -$22.6 million in 2025.
  • Its Change in Cash stands at -$22.6 million for Q3 2025, versus $21.8 million for Q2 2025 and $19462.2 for Q1 2025.